June 2012 | Oncology Live®

July 23, 2012

Although much has changed in cancer therapeutics, chemotherapy-induced nausea and vomiting remains a significant and much-feared adverse effect of treatment for many patients.

July 23, 2012

While ovarian cancer survival rates have improved slightly since the 1970s, the overall five-year survival for patients diagnosed with the tumor type lags behind the average rate of all cancers.

July 10, 2012

Hans-Peter Gerber has been building a program to develop novel biotherapeutics for oncology, including antibody-drug conjugates, at the Pfizer Oncology Research Unit in Pearl River, New York.

July 05, 2012

Antibodies directed against tumor cell antigens or overexpressed proteins are currently the fastest-growing class of targeted cancer therapeutics.

July 03, 2012

A summary of findings from the 43rd Annual Meeting on Women's Cancer with the potential to impact routine management of women with pelvic malignancies.

June 28, 2012

Three medical societies have joined in endorsing low-dose computed tomography screening for patients at high risk of developing lung cancer.

June 27, 2012

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

June 26, 2012

Most recurrent endometrial tumors have the same PI3K/Akt mutation profile as found in the primary tumor.

June 25, 2012

A recent study suggests patients may be selected for therapy based on the number of EGFR gene copies, and evaluated for clinical benefit based on the severity of the rash that often develops.